TP53 and acute myeloid leukemia: Additionally, in a very recent study investigating metabolic drivers of chemoresistance in TP53-mutated AML, it has been shown that TP53-mutated AML cells resist cytarabine-induced death through upregulation of one-carbon metabolism, that provides greater antioxidant capacity and better cytarabine-induced reactive oxygen species (ROS) management.